CytomX Therapeutics ( NASDAQ: CTMX ) on Monday announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. Ogden joined CytomX in August 2021 as Vice President, Finance and Accounting. He joined the company after a 16-year tenure at Eli Lilly, where he held senior financial leadership positions, including most recently as CFO of Lilly Diabetes.
CTMX -2.18% after hours to $1.34.
Source: Press Release . More on CytomX CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town.
